|
1
|
Lenis AT, Lec PM, Chamie K and Mshs MD:
Bladder cancer: A review. JAMA. 324:1980–1991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richters A, Aben KKH and Kiemeney L: The
global burden of urinary bladder cancer: An update. World J Urol.
38:1895–1904. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeGeorge KC, Holt HR and Hodges SC:
Bladder cancer: Diagnosis and Treatment. Am Fam Physician.
96:507–514. 2017.PubMed/NCBI
|
|
4
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Babjuk M, Burger M, Compérat EM, Gontero
P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF,
Sylvester R, et al: European association of urology guidelines on
non-muscle-invasive bladder cancer (TaT1 and carcinoma in
situ)-2019 update. Eur Urol. 76:639–657. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chang SS, Bochner BH, Chou R, Dreicer R,
Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, et
al: Treatment of non-metastatic muscle-invasive bladder cancer:
AUA/ASCO/ASTRO/SUO guideline. J Urol. 198:552–559. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder
cancer. Lancet. 388:2796–2810. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amiri M, Heshmatollah S, Esmaeilnasab N,
Khoubi J, Ghaderi E and Roshani D: Survival rate of patients with
bladder cancer and its related factors in Kurdistan province
(2013–2018): A population-based study. BMC Urol. 20:1952020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C
and Li B: Ferroptosis, a new form of cell death: Opportunities and
challenges in cancer. J Hematol Oncol. 12:342019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du Y, Miao W, Jiang X, Cao J, Wang B, Wang
Y, Yu J, Wang X and Liu H: The epithelial to mesenchymal transition
related gene calumenin is an adverse prognostic factor of bladder
cancer correlated with tumor microenvironment remodeling, gene
mutation, and ferroptosis. Front Oncol. 11:6839512021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen JN, Li T, Cheng L, Qin TS, Sun YX,
Chen CT, He YZ, Liu G, Yao D, Wei Y, et al: Synthesis and in vitro
anti-bladder cancer activity evaluation of quinazolinyl-arylurea
derivatives. Eur J Med Chem. 205:1126612020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo P, Wang L, Shang W, Chen J, Chen Z,
Xiong F, Wang Z, Tong Z, Wang K, Yang L, et al: Intravesical in
situ immunostimulatory gel for triple therapy of bladder cancer.
ACS Appl Mater Interfaces. 12:54367–54377. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang C, Zhang X, Yang M and Dong X:
Recent progress in ferroptosis inducers for cancer therapy. Adv
Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Ma H, Meng L, Liu X, Lv Z, Zhang Y
and Wang J: Construction and external validation of a
ferroptosis-related gene signature of predictive value for the
overall survival in bladder cancer. Front Mol Biosci. 8:6756512021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Z, Jensen MA and Zenklusen JC: A
practical guide to the cancer genome atlas (TCGA). Methods Mol
Biol. 1418:111–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS,
Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value
of progression-related gene classifier in primary non-muscle
invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chandrashekar DS, Chakravarthi B, Robinson
AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK,
Davuluri S, Guru MS, et al: Therapeutically actionable PAK4 is
amplified, overexpressed, and involved in bladder cancer
progression. Oncogene. 39:4077–4091. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu M, Ge Q, Wang G, Luo Y and Wang X,
Jiang W, Liu X, Wu CL, Xiao Y and Wang X: CIRBP is a novel oncogene
in human bladder cancer inducing expression of HIF-1α. Cell Death
Dis. 9:10462018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stockwell BR, Friedmann Angeli JP, Bayir
H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK,
Kagan VE, et al: Ferroptosis: A regulated cell death nexus linking
metabolism, redox biology, and disease. Cell. 171:273–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bersuker K, Hendricks JM, Li Z, Magtanong
L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al:
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit
ferroptosis. Nature. 575:688–692. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Doll S, Freitas FP, Shah R, Aldrovandi M,
da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius
E, Scheel CH, et al: FSP1 is a glutathione-independent ferroptosis
suppressor. Nature. 575:693–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szklarczyk D, Franceschini A, Kuhn M,
Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork
P, et al: The STRING database in 2011: Functional interaction
networks of proteins, globally integrated and scored. Nucleic Acids
Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simon N, Friedman J, Hastie T and
Tibshirani R: Regularization paths for Cox's proportional hazards
model via coordinate descent. J Stat Softw. 39:1–13. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tibshirani R: The lasso method for
variable selection in the Cox model. Stat Med. 16:385–395. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tran L, Xiao JF, Agarwal N, Duex JE and
Theodorescu D: Advances in bladder cancer biology and therapy. Nat
Rev Cancer. 21:104–121. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan C, Sun Y, Tian Y, Lu L, Dai X, Meng J,
Huang J, He Q, Wu B, Zhang Z, et al: Irradiated tumor cell-derived
microparticles mediate tumor eradication via cell killing and
immune reprogramming. Sci Adv. 6:eaay97892020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeuchi H, Tanaka M, Tanaka A, Tsunemi A
and Yamamoto H: Predominance of M2-polarized macrophages in bladder
cancer affects angiogenesis, tumor grade and invasiveness. Oncol
Lett. 11:3403–3408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takeuchi H, Taoka R, Mmeje CO, Jinesh GG,
Safe S and Kamat AM: CDODA-Me decreases specificity protein
transcription factors and induces apoptosis in bladder cancer cells
through induction of reactive oxygen species. Urol Oncol.
34:337.e11–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takeuchi H, Mmeje CO, Jinesh GG, Taoka R
and Kamat AM: Sequential gemcitabine and tamoxifen treatment
enhances apoptosis and blocks transformation in bladder cancer
cells. Oncol Rep. 34:2738–2744. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole
D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL,
et al: Drug-tolerant persister cancer cells are vulnerable to GPX4
inhibition. Nature. 551:247–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Viswanathan VS, Ryan MJ, Dhruv HD, Gill S,
Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada
K, Aguirre AJ, et al: Dependency of a therapy-resistant state of
cancer cells on a lipid peroxidase pathway. Nature. 547:453–457.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luan JC, Zeng TY, Zhang QJ, Xia DR, Cong
R, Yao LY, Song LB, Zhou X, Zhou X, Chen X, et al: A novel
signature constructed by ferroptosis-associated genes (FAGs) for
the prediction of prognosis in bladder urothelial carcinoma (BLCA)
and associated with immune infiltration. Cancer Cell Int.
21:4142021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu B, Lu X, Shen H, Yuan X, Wang X, Yin N,
Sun L, Shen P, Hu C, Jiang H and Wang D: Intratumoral heterogeneity
and genetic characteristics of prostate cancer. Int J Cancer.
146:3369–3378. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gulhati P, Bowen KA, Liu J, Stevens PD,
Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T and Evers
BM: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of
colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res.
71:3246–3256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu SC: Regulation of glutathione
synthesis. Mol Aspects Med. 30:42–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kajarabille N and Latunde-Dada GO:
Programmed cell-death by ferroptosis: Antioxidants as mitigators.
Int J Mol Sci. 20:49682019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhu L, Yang F, Wang L, Dong L, Huang Z,
Wang G, Chen G and Li Q: Identification the ferroptosis-related
gene signature in patients with esophageal adenocarcinoma. Cancer
Cell Int. 21:1242021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sharma P, Shimura T, Banwait JK and Goel
A: Andrographis-mediated chemosensitization through activation of
ferroptosis and suppression of β-catenin/Wnt-signaling pathways in
colorectal cancer. Carcinogenesis. 41:1385–1394. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma R, Shimura T, Yin C, Okugawa Y,
Kitajima T, Koike Y, Okita Y, Ohi M, Uchida K, Goel A, et al:
Antitumor effects of Andrographis via ferroptosis-associated genes
in gastric cancer. Oncol Lett. 22:5232021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang J, Liu J, Wu J, Li W, Chen Z and
Yang L: Progression of the role of CRYAB in signaling pathways and
cancers. Onco Targets Ther. 12:4129–4139. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu WF, Gong L, Cao Z, Ma H, Ji W, Deng M,
Liu M, Hu XH, Chen P, Yan Q, et al: αA- and αB-crystallins interact
with caspase-3 and Bax to guard mouse lens development. Curr Mol
Med. 12:177–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun X, Ou Z, Xie M, Kang R, Fan Y, Niu X,
Wang H, Cao L and Tang D: HSPB1 as a novel regulator of ferroptotic
cancer cell death. Oncogene. 34:5617–5625. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Christopher KL, Pedler MG, Shieh B, Ammar
DA, Petrash JM and Mueller NH: Alpha-crystallin-mediated protection
of lens cells against heat and oxidative stress-induced cell death.
Biochim Biophys Acta. 1843:309–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Prabhu S, Srinivas V, Ramakrishna T, Raman
B and Rao Ch M: Inhibition of Cu2+-mediated generation of reactive
oxygen species by the small heat shock protein αB-crystallin: The
relative contributions of the N- and C-terminal domains. Free Radic
Biol Med. 51:755–762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ruan H, Li Y, Wang X, Sun B, Fang W, Jiang
S and Liang C: CRYAB inhibits migration and invasion of bladder
cancer cells through the PI3K/AKT and ERK pathways. Jpn J Clin
Oncol. 50:254–260. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Feng H, Schorpp K, Jin J, Yozwiak CE,
Hoffstrom BG, Decker AM, Rajbhandari P, Stokes ME, Bender HG, Csuka
JM, et al: Transferrin receptor is a specific ferroptosis marker.
Cell Rep. 30:3411–3423.e7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Daniels TR, Bernabeu E, Rodríguez JA,
Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera
G and Penichet ML: The transferrin receptor and the targeted
delivery of therapeutic agents against cancer. Biochim Biophys
Acta. 1820:291–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yamamoto S and Bloch K: Studies on
squalene epoxidase of rat liver. J Biol Chem. 245:1670–1674. 1970.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xu H, Zhou S, Tang Q, Xia H and Bi F:
Cholesterol metabolism: New functions and therapeutic approaches in
cancer. Biochim Biophys Acta Rev Cancer. 1874:1883942020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jun SY, Brown AJ, Chua NK, Yoon JY, Lee
JJ, Yang JO, Jang I, Jeon SJ, Choi TI, Kim CH and Kim NS: Reduction
of squalene epoxidase by cholesterol accumulation accelerates
colorectal cancer progression and metastasis. Gastroenterology.
160:1194–1207.e28. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu D, Wong CC, Fu L, Chen H, Zhao L, Li
C, Zhou Y, Zhang Y, Xu W, Yang Y, et al: Squalene epoxidase drives
NAFLD-induced hepatocellular carcinoma and is a pharmaceutical
target. Sci Transl Med. 10:eaap98402018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gubelmann C, Schwalie PC, Raghav SK, Röder
E, Delessa T, Kiehlmann E, Waszak SM, Corsinotti A, Udin G,
Holcombe W, et al: Identification of the transcription factor ZEB1
as a central component of the adipogenic gene regulatory network.
Elife. 3:e033462014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hu T, Zhang C, Tang Q, Su Y, Li B, Chen L,
Zhang Z, Cai T and Zhu Y: Variant G6PD levels promote tumor cell
proliferation or apoptosis via the STAT3/5 pathway in the human
melanoma xenograft mouse model. BMC Cancer. 13:2512013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhang C, Zhang Z, Zhu Y and Qin S:
Glucose-6-phosphate dehydrogenase: A biomarker and potential
therapeutic target for cancer. Anticancer Agents Med Chem.
14:280–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L,
Wang L, Zhu W and Jia H: Elevated G6PD expression contributes to
migration and invasion of hepatocellular carcinoma cells by
inducing epithelial-mesenchymal transition. Acta Biochim Biophys
Sin (Shanghai). 50:370–380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen X, Xu Z, Zhu Z, Chen A, Fu G, Wang Y,
Pan H and Jin B: Modulation of G6PD affects bladder cancer via ROS
accumulation and the AKT pathway in vitro. Int J Oncol.
53:1703–1712. 2018.PubMed/NCBI
|
|
63
|
Yi J, Zhu J, Wu J, Thompson C and Jiang X:
Oncogenic activation of PI3K-AKT-mTOR signaling suppresses
ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA.
117:31189–31197. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang L, Liu W, Liu F, Wang Q, Song M, Yu
Q, Tang K, Teng T, Wu D, Wang X, et al: IMCA induces ferroptosis
mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal
cancer. Oxid Med Cell Longev. 2020:16756132020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang S, Chen S, Ying Y, Ma X, Shen H, Li
J, Wang X, Lin Y, Liu B, Zheng X and Xie L: Comprehensive analysis
of ferroptosis regulators with regard to PD-L1 and immune
infiltration in clear cell renal cell carcinoma. Front Cell Dev
Biol. 9:6761422021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jiang LR, Zhang N, Chen ST, He J, Liu YH,
Han YQ, Shi XQ, Yang JJ, Mu DY, Fu GH and Gao F: PD-1-positive
tumor-associated macrophages define poor clinical outcomes in
patients with muscle invasive bladder cancer through potential
CD68/PD-1 complex interactions. Front Oncol. 11:6799282021.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Krafft U, Olah C, Reis H, Kesch C, Darr C,
Grünwald V, Tschirdewahn S, Hadaschik B, Horvath O, Kenessey I, et
al: High serum PD-L1 levels are associated with poor survival in
urothelial cancer patients treated with chemotherapy and immune
checkpoint inhibitor therapy. Cancers (Basel). 13:25482021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
van Wilpe S, Gerretsen E, van der Heijden
A, de Vries I, Gerritsen W and Mehra N: Prognostic and predictive
value of tumor-infiltrating immune cells in urothelial cancer of
the bladder. Cancers (Basel). 12:26922020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gu M, Zhou X, Sohn JH, Zhu L, Jie Z, Yang
JY, Zheng X, Xie X, Yang J, Shi Y, et al: NF-κB-inducing kinase
maintains T cell metabolic fitness in antitumor immunity. Nat
Immunol. 22:193–204. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang Y, Swanda RV, Nie L, Liu X, Wang C,
Lee H, Lei G, Mao C, Koppula P, Cheng W, et al: mTORC1 couples
cyst(e)ine availability with GPX4 protein synthesis and ferroptosis
regulation. Nat Commun. 12:15892021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Chen D, Fan Z, Rauh M, Buchfelder M,
Eyupoglu IY and Savaskan N: ATF4 promotes angiogenesis and neuronal
cell death and confers ferroptosis in a xCT-dependent manner.
Oncogene. 36:5593–5608. 2017. View Article : Google Scholar : PubMed/NCBI
|
